News und Analysen
Why EXACT Sciences Corporation Jumped 13.2% in September
Shares of EXACT Sciences (NASDAQ: EXAS), a diagnostics company focused on colon cancer, rose more than 13% in September, according to data from S&P Global Market Intelligence. While it was a....
Why Cerus Corporation Stock Marched Higher Today
Shares of the biomedical company Cerus Corporation (NASDAQ: CERS) rose by as much as 14.5% today on more than triple the average volume. The company's shares took flight on the news that the U.S.....
Why ImmunoGen, Inc. Dropped Today
Shares of ImmunoGen (NASDAQ: IMGN) are down 11% at 3:29 p.m. EDT after announcing yesterday that it plans to sell 13 million shares through a secondary offering. Investors could be further diluted....
Big Day on Deck for Flexion Therapeutics
Flexion Therapeutics (NASDAQ: FLXN) is about to find out if its research efforts will pay off. The U.S. Food and Drug Administration is expected to issue a go/no-go decision on its treatment for....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 30 septembre 2017
Le 5 octobre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Shares of Exelixis (NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global....
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Shares of Exelixis (NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....
What Caused Sarepta Therapeutics to Rally 12.6% in September
After reporting early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics (NASDAQ: SRPT) jumped 12.6% last month,....
3 High-Yield Billionaire Stocks
Billionaire investors know a thing or two about picking stocks. That's why we Fools like to scan our favorite investors' holdings every couple of months to see what they have been buying and....
3 High-Yield Billionaire Stocks
Billionaire investors know a thing or two about picking stocks. That's why we Fools like to scan our favorite investors' holdings every couple of months to see what they have been buying and....
Why Shopify, Momenta Pharmaceuticals, and MBIA Slumped Today
The stock market saw new highs on Wednesday, even though gains for most major benchmarks were extremely small. Investors are trying to balance their enthusiasm about the U.S. economy and potential....
Here's Why Rigel Pharmaceuticals, Inc. Reversed Course Today
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) got off to a rocky start this morning, falling more than 8% before the market digested the details of a recently announced share offering. The....
Here's Why Strongbridge Biopharma Fell as Much as 20% Today
Shares of Strongbridge Biopharma (NASDAQ: SBBP) dropped 20% this morning after the rare-disease therapeutic developer announced the pricing of a share offering. The company will sell 4 million....
Here's Why NewLink Genetics Corp. Stock Is Surging Again Today
Shares of NewLink Genetics Corp. (NASDAQ: NLNK), a clinical stage biotech with an oncology focus, are rising in response to a secondary offering that ended up priced much better than anticipated.....
Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
If you're an investor, chances are you're well aware that it's been tough to surpass the returns from marijuana stocks over the past year. In late June, the average trailing 12-month return of the....
3 Top Small-Cap Stocks to Buy in October
Even though Halloween is coming, don't let all small-cap stocks scare you. While it's generally true that smaller businesses present higher risks to investors than larger companies do, they may....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....